Cumali Aktolun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cumali Aktolun has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
Fatma Berk
Kocaeli University School of Medicine
9 shared publicationsHakan Demir
Department of Nuclear Medicine, Kocaeli University Medical School, Derince, Kocaeli, Turkey
9 shared publications- Lorenzo Maffioli
ASST Ovest Milanese
8 shared publications Luc Mortelmans
University UZ Gasthuisberg
8 shared publicationsRichard P. Baum
PET Center
8 shared publications- Roy Moncayo
WOMED, Karl-Kapferer-Strasse 5, 6020 Innsbruck, Austria
7 shared publications
Latest Publications
- 28 November 2019
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 47 (2) , 513
Publisher Correction: Artificial intelligence and radiomics in nuclear medicine: potentials and challenges
The publisher regret to inform the readers that the original version of this article contained errors in the text and published inadvertently.
- 28 November 2019
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 47 (2) , 513
Publisher Correction: Artificial intelligence and radiomics in nuclear medicine: potentials and challenges
The publisher regret to inform the readers that the original version of this article contained errors in the text and published inadvertently.
- 31 October 2019
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 46 (13) , 2731-2736
Artificial intelligence and radiomics in nuclear medicine: potentials and challenges
Artificial intelligence involves a wide range of smart techniques that are applicable to medical services including nuclear medicine. Recent advances in computer power, availability of accumulated digital archives containing large amount of patient images, and records bring new opportunities for the implementation of artificial techniques in nuclear medicine. As a subset of artificial intelligence, machine learning is an emerging tool that can possibly perform many clinical tasks. Nuclear medicine community needs to adapt to this fast approaching smart era, to exploit the opportunities and tackle the problems associated with artificial intelligence tools. It is aimed in this editorial to outline the opportunities and challenges of artificial intelligence applications in nuclear medicine.
- 31 October 2019
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 46 (13) , 2731-2736
Artificial intelligence and radiomics in nuclear medicine: potentials and challenges
Artificial intelligence involves a wide range of smart techniques that are applicable to medical services including nuclear medicine. Recent advances in computer power, availability of accumulated digital archives containing large amount of patient images, and records bring new opportunities for the implementation of artificial techniques in nuclear medicine. As a subset of artificial intelligence, machine learning is an emerging tool that can possibly perform many clinical tasks. Nuclear medicine community needs to adapt to this fast approaching smart era, to exploit the opportunities and tackle the problems associated with artificial intelligence tools. It is aimed in this editorial to outline the opportunities and challenges of artificial intelligence applications in nuclear medicine.
- Top Cited Papers
- 1 January 2019
- Published by SAGE Publications in Thyroid®
- Vol. 29 (1) , 7-26
European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium
Background: The American Thyroid Association (ATA) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer (DTC) are highly influential practice recommendations. The latest revision appeared in 2015 (“ATA 2015”). These guidelines were developed predominantly by North American experts. European experts frequently have different perspectives, given epidemiological, technological/methodological, practice organization, and medicolegal differences between the respective regions. Summary: Divergent viewpoints were the focus of an invited symposium organized by the European Association of Nuclear Medicine involving 17 European thyroidologists, 4 ATA Guidelines Taskforce members, and an audience of 200 international experts. The group discussed “preoperative assessment of thyroid nodules,” “surgery and role of pathology,” “radioiodine therapy (RAIT),” “assessment of initial therapy and dynamic risk stratification,” and “treatment of persistent disease, recurrences, and advanced thyroid cancer.” The dialogue resulted in this position paper contrasting European and ATA 2015 perspectives on key issues. One difference pertains to ATA 2015’s permissiveness of lobectomy for primary tumors ≤4 cm. European panelists cited preclusion of RAIT, potential need for completion thyroidectomy, frequent inability to avoid chronic thyroid hormone replacement, and limitations of supportive evidence as arguments against widely applying lobectomy. Significant divergence involved ATA 2015’s guidance regarding RAIT. European panelists favored wider use of post-operative RAIT than does ATA 2015. Rationales included the modality’s association with favorable patient outcomes and generally limited toxicity, and lack of high-quality evidence supporting withholding RAIT. Additionally, European panelists favored recombinant human thyrotropin in more settings than does ATA 2015, citing avoidance of hypothyroid morbidity and quality-of-life impairment, without apparent sacrifice in oncologic outcomes. Based on clinicial evidence plus theoretical advantages, European experts advocated dosimetric versus fixed-activity RAIT approaches for advanced DTC. European panelists noted that the ATA 2015 risk stratification system requires information sometimes unavailable in everyday practice. ATA 2015 recommendations regarding radioiodine-refractory DTC should consider potential palliative benefits of RAIT in patients who also have radioiodine-susceptible lesions. Conclusions: European panelists suggested modifications to approximately one-third of ATA 2015 recommendations. Varying European and ATA 2015 perspectives can stimulate analysis and discussion of literature and performance of primary research to resolve discrepant recommendations and potentially improve patient outcomes.
- 1 January 2019
- Published by SAGE Publications in Thyroid®
- Vol. 29 (1) , 7-26
Top Cited PapersEuropean Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium
Background: The American Thyroid Association (ATA) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer (DTC) are highly influential practice recommendations. The latest revision appeared in 2015 (“ATA 2015”). These guidelines were developed predominantly by North American experts. European experts frequently have different perspectives, given epidemiological, technological/methodological, practice organization, and medicolegal differences between the respective regions. Summary: Divergent viewpoints were the focus of an invited symposium organized by the European Association of Nuclear Medicine involving 17 European thyroidologists, 4 ATA Guidelines Taskforce members, and an audience of 200 international experts. The group discussed “preoperative assessment of thyroid nodules,” “surgery and role of pathology,” “radioiodine therapy (RAIT),” “assessment of initial therapy and dynamic risk stratification,” and “treatment of persistent disease, recurrences, and advanced thyroid cancer.” The dialogue resulted in this position paper contrasting European and ATA 2015 perspectives on key issues. One difference pertains to ATA 2015’s permissiveness of lobectomy for primary tumors ≤4 cm. European panelists cited preclusion of RAIT, potential need for completion thyroidectomy, frequent inability to avoid chronic thyroid hormone replacement, and limitations of supportive evidence as arguments against widely applying lobectomy. Significant divergence involved ATA 2015’s guidance regarding RAIT. European panelists favored wider use of post-operative RAIT than does ATA 2015. Rationales included the modality’s association with favorable patient outcomes and generally limited toxicity, and lack of high-quality evidence supporting withholding RAIT. Additionally, European panelists favored recombinant human thyrotropin in more settings than does ATA 2015, citing avoidance of hypothyroid morbidity and quality-of-life impairment, without apparent sacrifice in oncologic outcomes. Based on clinicial evidence plus theoretical advantages, European experts advocated dosimetric versus fixed-activity RAIT approaches for advanced DTC. European panelists noted that the ATA 2015 risk stratification system requires information sometimes unavailable in everyday practice. ATA 2015 recommendations regarding radioiodine-refractory DTC should consider potential palliative benefits of RAIT in patients who also have radioiodine-susceptible lesions. Conclusions: European panelists suggested modifications to approximately one-third of ATA 2015 recommendations. Varying European and ATA 2015 perspectives can stimulate analysis and discussion of literature and performance of primary research to resolve discrepant recommendations and potentially improve patient outcomes.
- Open Access
- 16 February 2018
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 45 (5) , 846-859
EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides
The skeleton is the most common metastatic site in patients with advanced cancer. Pain is a major healthcare problem in patients with bone metastases. Bone-seeking radionuclides that selectively accumulate in the bone are used to treat cancer-induced bone pain and to prolong survival in selected groups of cancer patients. The goals of these guidelines are to assist nuclear medicine practitioners in: (a) evaluating patients who might be candidates for radionuclide treatment of bone metastases using beta-emitting radionuclides such as strontium-89 (89Sr), samarium-153 (153Sm) lexidronam (153Sm-EDTMP), and phosphorus-32 (32P) sodium phosphate; (b) performing the treatments; and ©) understanding and evaluating the treatment outcome and side effects.
- 16 February 2018
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 45 (5) , 846-859
Open AccessEANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides
The skeleton is the most common metastatic site in patients with advanced cancer. Pain is a major healthcare problem in patients with bone metastases. Bone-seeking radionuclides that selectively accumulate in the bone are used to treat cancer-induced bone pain and to prolong survival in selected groups of cancer patients. The goals of these guidelines are to assist nuclear medicine practitioners in: (a) evaluating patients who might be candidates for radionuclide treatment of bone metastases using beta-emitting radionuclides such as strontium-89 (89Sr), samarium-153 (153Sm) lexidronam (153Sm-EDTMP), and phosphorus-32 (32P) sodium phosphate; (b) performing the treatments; and ©) understanding and evaluating the treatment outcome and side effects.
- 27 April 2016
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 43 (8) , 1486-1490
The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of Nuclear Medicine
- 27 April 2016
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 43 (8) , 1486-1490
The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of Nuclear Medicine
- 17 February 2016
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 43 (6) , 1001-1005
Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer
- 17 February 2016
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 43 (6) , 1001-1005
Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer
- 1 December 2014
- Vol. 7 (12) , 8941-6
Utility of F-18 fluorodeoxyglucose posıtron emıssıon tomography/computed ın carcınoma of unknown primary.
Carcinoma of unknown primary (CUP) is a heterogeneous group of tumors with various clinical features causing diagnostic and therapeutic challenges. The aim of this study was to evaluate the ability of F-18 FDG PET/CT for localizing the primary tumor, disclosing additional metastases, and changing the treatment in patients with CUP. One hundred and twelve metastatic patients (female = 40, male = 72, median age = 60.5 years) in whom conventional diagnostic work-up failed to disclose the primary tumor were included in the study. F-18 FDG PET/CT imaging was performed in a standard protocol (patient supine, arms on patient's side, vertex to thigh, 369.3 MBq (296-444 MBq) F-18 FDG, a 60-minute uptake period, 6-7 bed position). Histopathology was taken as the only reference standard. F-18 FDG PET/CT correctly detected primary tumor in 37 of 112 (33.03%) patients. The most common site of primary tumor detected by F-18 FDG PET/CT was lung (n = 18), which was followed by nasopharynx (n = 7), pancreas (n = 5), tonsil (n = 2), breast (n = 2), thyroid (n = 1), uterus (n = 1) and colon/rectum (n = 1). F-18 FDG PET/CT imaging disclosed additional previously undetected metastases in 32 (28.5%) and changed the treatment in 33 (29.4%) of 112 patients. There were false positive F-18 FDG PET/CT results in 21 (18.5%) patients. F-18 FDG PET/CT is able to disclose the primary tumor, disclose new metatases and change the treatment in about one third of patients with CUP.
- 1 December 2014
- Vol. 7 (12) , 8941-6
Utility of F-18 fluorodeoxyglucose posıtron emıssıon tomography/computed ın carcınoma of unknown primary.
Carcinoma of unknown primary (CUP) is a heterogeneous group of tumors with various clinical features causing diagnostic and therapeutic challenges. The aim of this study was to evaluate the ability of F-18 FDG PET/CT for localizing the primary tumor, disclosing additional metastases, and changing the treatment in patients with CUP. One hundred and twelve metastatic patients (female = 40, male = 72, median age = 60.5 years) in whom conventional diagnostic work-up failed to disclose the primary tumor were included in the study. F-18 FDG PET/CT imaging was performed in a standard protocol (patient supine, arms on patient's side, vertex to thigh, 369.3 MBq (296-444 MBq) F-18 FDG, a 60-minute uptake period, 6-7 bed position). Histopathology was taken as the only reference standard. F-18 FDG PET/CT correctly detected primary tumor in 37 of 112 (33.03%) patients. The most common site of primary tumor detected by F-18 FDG PET/CT was lung (n = 18), which was followed by nasopharynx (n = 7), pancreas (n = 5), tonsil (n = 2), breast (n = 2), thyroid (n = 1), uterus (n = 1) and colon/rectum (n = 1). F-18 FDG PET/CT imaging disclosed additional previously undetected metastases in 32 (28.5%) and changed the treatment in 33 (29.4%) of 112 patients. There were false positive F-18 FDG PET/CT results in 21 (18.5%) patients. F-18 FDG PET/CT is able to disclose the primary tumor, disclose new metatases and change the treatment in about one third of patients with CUP.
- 1 June 2013
- Vol. 57 (2) , 109-11
Diagnostic and therapeutic use of MIBG in pheochromocytoma and paraganglioma.
- 1 June 2013
- Vol. 57 (2) , 109-11
Diagnostic and therapeutic use of MIBG in pheochromocytoma and paraganglioma.
- 1 June 2013
- Vol. 57 (2) , 146-52
Iodine-131 metaiodobenzylguanidine (I-131 MIBG) diagnosis and therapy of pheochromocytoma and paraganglioma: current problems, critical issues and presentation of a sample case.
Iodine-131 metaiodobenzylguanidine (I-131 MIBG) has been used for the diagnosis and treatment of malignant pheochromocytomas (PHEO) and paragangliomas (PGL) since 1980's. Despite increasing amount of experience with iodine-131 (I-131) MIBG therapy, many important questions still exist. In this article, we will discuss the current problems learned from clinical experience in diagnosis and therapy of PHEO/PGL with I-131 MIBG, and present a sample case to emphasize the critical aspects for an optimal treatment strategy.
- 1 June 2013
- Vol. 57 (2) , 146-52
Iodine-131 metaiodobenzylguanidine (I-131 MIBG) diagnosis and therapy of pheochromocytoma and paraganglioma: current problems, critical issues and presentation of a sample case.
Iodine-131 metaiodobenzylguanidine (I-131 MIBG) has been used for the diagnosis and treatment of malignant pheochromocytomas (PHEO) and paragangliomas (PGL) since 1980's. Despite increasing amount of experience with iodine-131 (I-131) MIBG therapy, many important questions still exist. In this article, we will discuss the current problems learned from clinical experience in diagnosis and therapy of PHEO/PGL with I-131 MIBG, and present a sample case to emphasize the critical aspects for an optimal treatment strategy.